PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1851559
				PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1851559
The arthroscopy devices market size stands at USD 1.74 billion in 2025 and is forecast to reach USD 2.31 billion by 2030, advancing at a 5.69% CAGR.

Demand acceleration reflects the continued shift toward minimally invasive joint repair, the steady rise in musculoskeletal disease prevalence, and widening adoption of outpatient surgical pathways. Device makers now bundle visualization, resection, and implant systems to capture more value per procedure, while payors reward settings that deliver equal outcomes at lower cost. Artificial-intelligence guidance, wireless imaging, and bio-integrative implants raise both clinical efficacy and pricing power. At the same time, sustainability regulations and single-use scrutiny stimulate research into recyclable or hybrid portfolios. Competitive strategies concentrate on acquisitions that secure breakthrough technologies or fill geographic gaps, keeping sector consolidation in a moderate zone.
Global osteoarthritis cases reached 606.5 million in 2021, with prevalence accelerating among women and the elderly. Musculoskeletal disease now ranks as the second-largest cause of years lived with disability, pushing payors toward cost-effective arthroscopic solutions. Projections suggest that nearly 50% of post-menopausal women could have osteoarthritis by 2045. Demand growth therefore aligns directly with demographic aging and rising life expectancy in both developed and emerging regions.
Average hospital stay falls by 2-3 days when arthroscopy replaces open surgery, translating to measurable payor savings and improved patient satisfaction. Uptake is further propelled by 4K visualization, wireless cameras, and robotic assistance that expand indications once considered too complex for a portal approach. Younger patients favor the faster rehabilitation and smaller scars relative to open repair.
A fully equipped arthroscopy suite requires upfront investment above USD 500,000, while consumables add USD 2,000-5,000 per case, pressuring facilities with modest volumes. Inventory demands escalate when covering multiple joints, and reimbursement often fails to offset the premium of single-use disposables.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Knee procedures accounted for 45.23% of 2024 revenues, underscoring the joint's high injury incidence and the maturity of arthroscopic ACL and meniscus repair protocols. Stable reimbursement and extensive surgeon familiarity cement volume leadership. Hip arthroscopy, although smaller today, is growing at a 7.67% CAGR on wider recognition of femoroacetabular impingement and labral tears in younger athletes. Access-refining cannulas and flexible burrs mitigate the steep learning curve, opening the segment to more community hospitals. Shoulder and elbow scopes benefit from bio-inductive patch implants that cut re-tear rates, while endoscopic spine portals inch into mainstream as companies extend platforms to disc decompression. Collectively, procedure mix is tilting from diagnostic lavage to reconstructive repair, a shift that lifts average selling price across the arthroscopy devices market.
The arthroscopy devices market size for knee interventions is projected to advance steadily through 2030, supported by sports-related ligament repair and degenerative meniscus management. In contrast, hip procedures hold only a mid-teens share today but are forecast to command a materially larger slice of the arthroscopy devices market share as implants, pumps, and visualization systems adapt to deep-joint ergonomics. Varied joint adoption rates keep manufacturers investing in joint-specific shaver burrs, suture passers, and fixation anchors, reinforcing segmentation in their catalogs and service models.
The Arthroscopy Devices Market Report is Segmented by Application (Knee, Shoulder & Elbow, Hip, and More), Product (Arthroscopes, Arthroscopic Implants, and More), End User (Hospitals, Ascs, Orthopedic & Sports Medicine Clinics), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
North America generated 42.43% of 2024 sales, underpinned by high training capacity, strong insurer coverage, and a population that remains physically active into older age. The United States drives most demand; Medicare's 3.8% outpatient rate update sustains hospital margins while validating ASC migration. Canada's single-payer model steadies annual procedure counts, and Mexico's growing medical tourism market draws patients seeking lower-priced arthroscopic repair.
Europe ranks second in revenue, balancing strict regulation with a large base of skilled surgeons. The EU's push for greener devices encourages early adoption of reusable shaver handpieces and recyclable tubing. Aging demographics feed hip and shoulder volumes, and national sports programs keep knee scopes common among younger cohorts. Clinical-outcome evidence requirements foster tight links between suppliers and academic centers that run prospective registries, strengthening the data core of the arthroscopy devices market.
Asia-Pacific is the fastest-growing region at a 6.54% CAGR. China's centralized procurement lowers implant pricing, allowing wider hospital penetration. Domestic OEMs emerge, but international brands retain a technology edge in 4K visualization and navigation. Japan's robotics leadership supports the rollout of AI-guided portals, and its super-aging society guarantees steady case growth. India's public-private partnerships fund new arthroscopy labs, and government Make-in-India policies spur local assembly to lower import duties. Southeast Asian countries expand private insurance coverage, unlocking elective knee arthroscopy demand among a burgeoning middle class. Collectively, rising disposable income and improved hospital capacity translate into sustained volume gains across the arthroscopy devices market.